Advertisement

Trending Stories


Maternal diet during pregnancy and lactation leads to epigenetic changes in…


Surprising bone health findings in women with restless legs syndrome


Majority of breast cancer patients develop symptoms of post-traumatic stress disorder


New procedure allows kidney transplants from incompatible donors


Calgary researchers develop new class of nanomedicines to treat autoimmune diseases


UCLA-led researchers identify specific gene network that promotes repair in periphera…

Latest News


NIH-funded investigators develop therapeutic compound effective against malaria


Tai chi exercise improves outcomes in older fallers


Beta-blockers could have potential benefit for COPD patients


Foundation Surgical Hospital of El Paso receives Center of Excellence Award in Nursing


New research shows deficiencies in general palliative care for stroke…


Ultrasonic 'piezosurgery' equipment reduces pain, swelling in patients undergoi…

FDA grants three years of marketing exclusivity to ISTA's BROMDAY

Published on November 18, 2010 at 12:39 AM · No Comments

Recommend 0 Share 7 G+1 Tweet

ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced the U.S. Food and Drug Administration (FDA) has granted the Company three years of marketing exclusivity for BROMDAY™ (bromfenac ophthalmic solution) 0.09%, as provided under the Drug Price Competition and Patent Term Restoration Act, commonly known as the Hatch-Waxman Act. BROMDAY (formerly referred to as XiDay), the first and only once-daily prescription eye drop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction, was approved by the FDA in October of 2010. Under the Hatch-Waxman Act, the FDA may not approve an Abbreviated New Drug Application for a generic version of BROMDAY until October of 2013.

ISTA also announced it recently shipped the first orders of BROMDAY to wholesalers and expects BROMDAY to be available in pharmacies beginning the week of November 22, 2010. The ISTA sales force has begun detailing BROMDAY to ophthalmologists, and the company expects to discontinue the twice-daily XIBROM product in early 2011.

Source:
ISTA Pharmaceuticals, Inc.

Be the first to rate this post

Posted in: Pharmaceutical News
Tags: Allergy, Anti-Inflammatory, Cataract, Conjunctivitis, Contact Lens, Dry Eye, Glaucoma, New Drug Application, Pain

Permalink | Comments (0)

Prior News
VX-770 drug candidate improves lung function in people with cystic fibrosis

Next News
Rheonix receives U.S patent for microfluidic device

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Norsk | Русский | Svenska | Polski

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Post a new comment
Login
Quirky Comment Title (optional)
Post

Advertisement

DOCKET ALARM
IPR2015-01099 IPR2015-01097 IPR2015-01100 IPR2015-01105
Lupin EX1132
Page 1
Find authenticated court documents without watermarks at docketalarm.com.

News Medical
245,975 likes

Like Page Share

Be the first of your friends to like this

News Medical

Follow +1

+ 4,622

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.

AZO NETWORK
News-Medical.net - An AZoNetwork Site
Owned and Operated by AZoM.com Limited Copyright 2000-2016

HON CODE CERTIFIED 04/2015

This site complies with the HONcode standard for trustworthy health information: verify here.

DOCKET ALARM

Find authenticated court documents without watermarks at docketalarm.com.